Literature DB >> 15279907

Functional significance of the BBXXB motif reversed present in the cytoplasmic domains of the human follicle-stimulating hormone receptor.

Carlos Timossi1, Carmen Ortiz-Elizondo, David B Pineda, James A Dias, P Michael Conn, Alfredo Ulloa-Aguirre.   

Abstract

The minimal structural motif, BBXXB (where B represents a basic amino acid residue and X a non-basic residue), located in particular regions of the intracellular domains of cell surface membrane receptors is involved in the G protein-activating activity of a number of G protein-coupled receptors. The human FSH receptor (hFSHR) exhibits a reversed BBXXB motif (BXXBB) in the juxtamembrane region of the third intracellular loop (IL3) and the carboxyl terminus (Ctail) of the receptor; however the importance of this sequence on receptor function remains unclear. In the present study, we analyzed the effects of mutations in this structural motif on hFSHR expression, receptor-mediated effector activation and agonist-provoked receptor internalization. Human embryonic kidney 293 cells were transiently transfected with plasmids containing the cDNA of the wild-type (Wt) hFSHR or several hFSHR mutants in which basic amino acids of the minimal structural motif at the IL3 and Ctail were replaced with alanine (i.e. AXXAA, AXXBB, BXXAB and BXXBA mutants). Alanine substitution of the three basic residues present in the IL3-BXXBB (IL3-AXXAA mutant) yielded a < or =60 kDa possibly under-glycosylated form of the FSHR, whereas the same substitutions in the Ctail resulted in the immature >62 kDa form of the receptor; both AXXAA hFSHR mutants completely failed to bind agonist and activate effector. Individual substitutions resulted in different cAMP responses to agonist stimulation: the IL3-AXXBB and IL3-BXXBA mutant hFSHRs failed to evoke Gs protein activation, whereas agonist-stimulated cAMP production was completely normal when the IL3-BXXAB mutant was expressed. All three IL3 mutants bound [125I]-labelled FSH in a similar fashion to the Wt hFSHR. Ligand-binding, cell surface membrane receptor expression and agonist-provoked effector activation were significantly affected by the individual substitutions at the Ctail-BXXBB motif: the Ctail-AXXBB variant exhibited reduced (approximately 50%) maximal cAMP response and ability to bind ligand, whereas both ligand binding and effector activation was severely reduced or abolished by expression of the Ctail-BXXBA and -BXXAB hFSHR mutants; the expression levels of the 80 kDa form of the receptor correlated with the magnitude of ligand-provoked cAMP production and binding capability of the mutant receptors. Upon stimulation by agonist, all mutants with detectable ligand-binding activity internalized following the pattern exhibited by the Wt hFSHR species. These results indicate that the BXXBB motif at the IL3 of the hFSHR is essential for coupling the activated receptor to the Gs protein, whereas the same motif in the Ctail is apparently more important for membrane expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15279907     DOI: 10.1016/j.mce.2004.06.004

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  16 in total

1.  Characterization of intracellular signaling mediated by human somatostatin receptor 5: role of the DRY motif and the third intracellular loop.

Authors:  Erika Peverelli; Andrea G Lania; Giovanna Mantovani; Paolo Beck-Peccoz; Anna Spada
Journal:  Endocrinology       Date:  2009-04-02       Impact factor: 4.736

Review 2.  Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function.

Authors:  Alfredo Ulloa-Aguirre; Teresa Zariñán; James A Dias; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2013-06-24       Impact factor: 4.102

3.  Role of the intracellular domains of the human FSH receptor in G(alphaS) protein coupling and receptor expression.

Authors:  Alfredo Ulloa-Aguirre; Aída Uribe; Teresa Zariñán; Ismael Bustos-Jaimes; Marco A Pérez-Solis; James A Dias
Journal:  Mol Cell Endocrinol       Date:  2006-10-12       Impact factor: 4.102

4.  Dominant negative effects of human follicle-stimulating hormone receptor expression-deficient mutants on wild-type receptor cell surface expression. Rescue of oligomerization-dependent defective receptor expression by using cognate decoys.

Authors:  Teresa Zariñán; Marco A Perez-Solís; Guadalupe Maya-Núñez; Patricia Casas-González; P Michael Conn; James A Dias; Alfredo Ulloa-Aguirre
Journal:  Mol Cell Endocrinol       Date:  2010-03-04       Impact factor: 4.102

5.  The third intracellular loop stabilizes the inactive state of the neuropeptide Y1 receptor.

Authors:  Melissa J S Chee; Karin Mörl; Diana Lindner; Nicole Merten; Gerald W Zamponi; Peter E Light; Annette G Beck-Sickinger; William F Colmers
Journal:  J Biol Chem       Date:  2008-09-23       Impact factor: 5.157

6.  Trafficking of the follitropin receptor.

Authors:  Alfredo Ulloa-Aguirre; James A Dias; George Bousfield; Ilpo Huhtaniemi; Eric Reiter
Journal:  Methods Enzymol       Date:  2013       Impact factor: 1.600

7.  Increased plasma membrane expression of human follicle-stimulating hormone receptor by a small molecule thienopyr(im)idine.

Authors:  Jo Ann Janovick; Guadalupe Maya-Núñez; Alfredo Ulloa-Aguirre; Ilpo T Huhtaniemi; James A Dias; Pieter Verbost; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2008-09-20       Impact factor: 4.102

8.  Amyloid precursor proteins interact with the heterotrimeric G protein Go in the control of neuronal migration.

Authors:  Jenna M Ramaker; Tracy L Swanson; Philip F Copenhaver
Journal:  J Neurosci       Date:  2013-06-12       Impact factor: 6.167

Review 9.  Multiple facets of follicle-stimulating hormone receptor function.

Authors:  Alfredo Ulloa-Aguirre; Teresa Zariñán; Ana Ma Pasapera; Patricia Casas-González; James A Dias
Journal:  Endocrine       Date:  2008-02-02       Impact factor: 3.633

Review 10.  APP Receptor? To Be or Not To Be.

Authors:  Carole Deyts; Gopal Thinakaran; Angèle T Parent
Journal:  Trends Pharmacol Sci       Date:  2016-01-31       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.